A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

Neuropsychobiology

Volumn 50, Issue 1, 2004, Pages 57-64

  Montgomery, S A ^a   Huusom, A K T ^b   Bothmer, J ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

^c Lundbeck GmbH   (Germany)

Author keywords

Escitalopram, depression; Major depressive disorder, drug responsiveness; Venlafaxine XR, depression

Indexed keywords

ESCITALOPRAM; PLACEBO; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CONSTIPATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PRIMARY HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES; SWEATING; TREATMENT OUTCOME;

EID: 2642585582     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078225     Document Type: Article

References (33)

1. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL: The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993;150:720-727.
2. Montgomery SA: Clinically relevant effect sizes in depression. Eur Neuropsychopharm 1994;4:283-284.
3. Bostwick JM, Pankratz VS: Affective disorders and suicide risk: A reexamination. Am J Psychiatry 2000;157:1925-1932.
4. Lin EH, Von Korff M, Katon W, et al: The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
5. Katon W, Rutter C, Ludman EJ, et al: A randomized trial of relapse prevention of depression in primary care. Arch Gen Psychiatry 2001;58:241-247.
6. Gumnick JF, Nemeroff CB: Problems with currently available antidepressants. J Clin Psychiatry 2000;61(suppl 10):5-15.
7. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 1. Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43.
8. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
9. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-350.
10. Gorman J, Korotzer A, Su G: Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectrums 2002;7(suppl 4):40-44.
11. Lepola UM, Loft H, Reines EH: Escitalopram (10 to 20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-217.
12. Auquier P, Robitail S, Llorca P-M, Rive B: Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Prac 2003;7:259-268.
13. Cunningham LA, for the Venlafaxine XR 208 Study Group: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997;9:157-164.
14. Wade A, Lemming OM, Hedegaard KB: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
15. Rudolph RL, Feiger AD: A double-blind, randomised, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181.
16. ICH: ICH Harmonised Tripartite Guideline E6. Guideline for Good Clinical Practice. 1996. www.ich.org/pdfICH/e6.pdf.
17. APA: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
18. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
19. Hamilton M: Rating scale for depression. J Neurol Neurosur Psychiatry 1960;23:56-62.
20. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
21. Rosenbaum JF, Fava M, Hoog SL, et al: Selective serotonin reuptake inhibitor discontinuation syndrome: A randomised clinical trial. Biol Psychiatry 1998;44:77-87.
22. Montgomery SA, Rasmussen JGC, Tanghøj P: A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-188.
23. Montgomery S, Roberts A, Patel AG: Placebocontrolled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacol 1994;9(suppl 1):49-53.
24. Pérez V, Gilaberte I, Faries D, Alvarez E, Artigas F: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597.
25. Bielski R, Ventura D, Chang C, Korotzer A: Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2003;13(suppl 4):S262.
26. Montgomery SA: Alternatives to placebo-controlled trials in psychiatry. ECNP Consensus Meeting, September 26, 1996, Amsterdam. Eur Neuropsychopharmacol 1999;9:265-269.
27. Linden M, Ludewig K, Munz T, Dierkes W: Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: Results of a drug utilization observation study. Pharmacopsychiatry 2003;36:197-205.
28. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM: Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. J Clin Pharmacol 1999;48:345-354.
29. Bitsios P, Szabadi E, Bradshaw CM: Comparison of the effects of venlafaxine, paroxetine and desipramine on the papillary light reflex in man. Psychopharmacology 1999;143:286-292.
30. Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Exp Opin Pharmacother 2000;1:771-782.
31. Hindmarch I, Kimber S, Cockle SM: Abrupt and brief discontinuation of antidepressant treatment: Effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000;15:305-318.
32. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-368.
33. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF: Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154:1760-1762.